Background
CAD, deaths, T2DM, heart disease
HEART DISEASE, TYPE 2 DIABETES, EVENTS, CORONARY ARTERY DISEASE, CAD
One in four of the world’s population is of South Asian descent yet South Asian individuals account for approximately 60% of heart disease cases and half of cardiovascular (CV) deaths globally [Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally conceived as antihyperglycaemic agents, favourably lower the risk of CV events in people living with T2DM albeit with some heterogeneity [The EMPA-HEART (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes) CardioLink-6 trial studied individuals with T2DM and coronary artery disease (CAD) and reported that empagliflozin assignment for 6 months led to significant reduction of left ventricular (LV) mass (LVM) indexed to body surface area (BSA) at baseline (LVMi) [